SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CALO', Girolamo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.347
EU - Europa 4.935
AS - Asia 4.001
SA - Sud America 29
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 11
AF - Africa 2
Totale 32.339
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 23.270
CN - Cina 1.979
UA - Ucraina 1.380
DE - Germania 953
SG - Singapore 936
IT - Italia 885
TR - Turchia 867
GB - Regno Unito 679
FI - Finlandia 357
SE - Svezia 320
PL - Polonia 87
ID - Indonesia 81
CA - Canada 76
BE - Belgio 74
FR - Francia 54
RU - Federazione Russa 54
VN - Vietnam 49
CZ - Repubblica Ceca 27
IN - India 23
IR - Iran 16
LT - Lituania 15
HK - Hong Kong 14
BR - Brasile 13
JP - Giappone 12
NL - Olanda 12
CL - Cile 11
AU - Australia 7
NZ - Nuova Zelanda 7
A2 - ???statistics.table.value.countryCode.A2??? 6
KR - Corea 6
AT - Austria 5
EU - Europa 5
IQ - Iraq 4
AR - Argentina 3
DK - Danimarca 3
GR - Grecia 3
HR - Croazia 3
IE - Irlanda 3
LU - Lussemburgo 3
NO - Norvegia 3
RO - Romania 3
BG - Bulgaria 2
CH - Svizzera 2
ES - Italia 2
YE - Yemen 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BD - Bangladesh 1
BS - Bahamas 1
DZ - Algeria 1
EC - Ecuador 1
EE - Estonia 1
IL - Israele 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
MC - Monaco 1
MD - Moldavia 1
MM - Myanmar 1
MY - Malesia 1
NP - Nepal 1
PE - Perù 1
PH - Filippine 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
ZA - Sudafrica 1
Totale 32.339
Salva come PNG Salva come JPEG
Città #
Fairfield 3.307
Woodbridge 2.890
Houston 1.957
Ashburn 1.620
Jacksonville 1.591
Ann Arbor 1.518
Chandler 1.392
Seattle 1.339
Wilmington 1.180
Cambridge 1.156
Singapore 734
Santa Clara 653
Izmir 546
Nanjing 456
Princeton 355
Beijing 350
Ferrara 304
San Diego 280
Boardman 263
Milan 197
New York 197
Shanghai 194
Nanchang 137
Shenyang 129
Dearborn 127
Los Angeles 122
Falls Church 92
Warsaw 82
Hebei 81
Jakarta 81
San Mateo 81
Norwalk 78
Jiaxing 75
Bremen 74
Tianjin 74
Brussels 71
Munich 69
Changsha 67
Helsinki 66
London 66
Redwood City 64
Mountain View 63
Jinan 57
Addison 48
Auburn Hills 48
Dong Ket 45
Kunming 43
Washington 42
Zhengzhou 41
Philadelphia 38
Guangzhou 32
Mcallen 30
Montréal 29
Tappahannock 28
Toronto 28
Des Moines 27
Ningbo 27
Orange 27
Bologna 26
Indiana 26
Fuzhou 20
Verona 20
Brno 18
Lanzhou 18
Redmond 18
Leawood 17
Padova 17
Augusta 16
Hangzhou 15
Frankfurt am Main 13
Hounslow 12
Ottawa 11
Taizhou 11
Düsseldorf 10
Ardabil 9
Bari 8
Changchun 8
Florence 7
Hefei 7
Prescot 7
Walnut 7
Espoo 6
Ferrara di Monte Baldo 6
Hong Kong 6
Islington 6
Kilburn 6
Olomouc 6
San Francisco 6
Springfield 6
Amsterdam 5
Chiswick 5
Falkenstein 5
Haikou 5
La Canada Flintridge 5
Monmouth Junction 5
Mumbai 5
Rome 5
Yellow Springs 5
Boston 4
Central District 4
Totale 25.190
Salva come PNG Salva come JPEG
Nome #
Chimeric G proteins in fluorimetric calcium assays: Experience with opioid receptors 244
AGONISTI PIENI E PARZIALI ED ANTAGONISTI DEL RECETTORE PER NOCICETTINA/ORFANINA FQ AD ELEVATA POTENZA” 208
null 205
A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism 175
A novel and facile synthesis of tetra branched derivatives of nociceptin/orphanin FQ 169
Characterization of FR 172357, a new non-peptide bradykinin B2 receptor antagonist, in human, pig and rabbit preparations 169
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 166
Structural Bacterial Molecules as Potential Candidates for an Evolution of the Classical Concept of Probiotics 164
Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide. 150
Human vascular kinin receptors of the B-2 type characterized by radioligand binding 149
Kinin B-1 and B-2 receptors in pig vessels: characterization of two monoreceptor systems 148
A new selective antagonist of the nociceptin receptor 146
[Dmt(1) ]N/OFQ(1-13)-NH(2) , a potent nociceptin/orphanin FQ and opioid receptor universal agonist. 145
N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands 144
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor 143
Behavioural phenotypic characterization of CD-1 mice lacking the neuropeptide S receptor 143
Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze. 142
Structure activity studies of nociceptin/orphanin FQ(1–13)-NH2 derivatives modified in position 5 142
Tryptophan replacement in the nociceptin/orphanin FQ receptor ligand Ac-RYYRWK-NH2 140
Conformation-activity relationship of neuropeptide S and some structural mutants: Helicity affects their interaction with the receptor 139
Pharmacological profile of nociceptin/orphanin FQ receptors interacting with G-proteins and β-arrestins 2 138
Emergency admissions of opioid drug-abusers for overdose. A chronobiological study of enhanced risk 137
Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity 137
Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic- versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands 137
Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor 136
Intrathecal administration of nociceptin/orphanin FQ receptor agonists in rats: A strategy to relieve chemotherapy-induced neuropathic hypersensitivity 136
Pharmacological characterization of nociceptin receptor: an in vitro study 136
Nociceptin/orphanin FQ induces simultaneously anxiolytic and amnesic effects in the mouse elevated T-maze task. 134
A new ligand for the urotensin II receptor 134
[D-Pen(p-tBuBzl)5]NPS, a novel ligand for the neuropeptide S receptor: structure activity and pharmacological studies 134
Characterisation of the novel mixed Mu-NOP peptide ligand dermorphin-N/OFQ (DeNo) 134
Modulation of the NOP receptor signaling affects resilience to acute stress 134
A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials 134
Ring size in cyclic endomorphin-2 analogs modulates receptor binding affinity and selectivity 133
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor 132
UFP-112 a Potent and Long-Lasting Agonist Selective for the Nociceptin/Orphanin FQ Receptor 132
Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist 131
In vitro pharmacological characterisation of a novel cyclic nociceptin/orphanin FQ analogue c[Cys(7,10)]N/OFQ(1-13)NH2 130
Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt(1)]N/OFQ(1-13) 130
Structure-and conformation-Activity studies of nociceptin/orphanin FQ receptor dimeric ligands 130
Synthesis and biological activity of human neuropeptide S analogues modified in position 2 129
Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111 129
Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems 129
Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test 129
Pharmacology of [Tyr(1)]nociceptin analogs: receptor binding and bioassay studies 128
Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction 128
Effects of vasoactive agents in healthy and diseased human saphenous veins 128
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease 127
AMPA receptor activation regulates the glutamate metabotropic receptor stimulated phosphatidylinositol turnover in human cerebral cortex slices 126
UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ; Behavioral and electrophysiological studies in mice 125
Electrocardiographic alterations as a result of acute intoxication with fluvoxamine and pipamperone 125
Cardiovascular effects of nociceptin in unanesthetized mice 124
Antidepressant activity of nociceptin/orphanin FQ receptor antagonists in the mouse learned helplessness 124
[(t)Bu-d-Gly(5)]NPS, a pure and potent antagonist of the neuropeptide S receptor: In vitro and in vivo studies 123
Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs. 123
The Importance of Ligand-Receptor Conformational Pairs in Stabilization: Spotlight on the N/OFQ G Protein-Coupled Receptor 123
Further studies on nociceptin-related peptides: Discovery of a new chemical template with antagonist activity on the nociceptin receptor 122
Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: Pharmacological and genetic evidences 121
Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist 121
[Nphe(1)]nociceptin-(1-13)-NH2 antagonizes nociceptin effects in the mouse colon 120
Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands 120
Address and message sequences for the nociceptin receptor: A structure-activity study of nociceptin-(1-13)-peptide amide 120
Synthesis of mixed MOR/KOR efficacy cyclic opioid peptide analogs with antinociceptive activity after systemic administration 120
In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403 120
Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11) 119
Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: In vitro and in vivo studies 119
Selective breeding for high anxiety introduces a synonymous SNP that increases neuropeptide s receptor activity 119
Pharmacological characterization of the nociceptin receptor mediating hyperphagia: identification of a selective antagonist 118
Effects of neuropeptide S on seizures and oxidative damage induced by pentylenetetrazole in mice. 118
Actual concept of "probiotics": is it more functional to science or business? 118
Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24. 118
Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists. 118
[Nphe(1)]N/OFQ-(1-13)-NH2 is a competitive and selective antagonist at nociceptin/orphanin FQ receptors mediating K+ channel activation in rat periaqueductal gray slices 117
Effects of chronic nociceptin/orphanin FQ exposure on cAMP accumulation and receptor density in Chinese, hamster ovary cells expressing human nociceptin/orphanin FQ receptors 117
Pharmacological characterization of tachykinin tetrabranched derivatives 117
Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies 116
Structure-activity study at positions 3 and 4 of human neuropeptide S. 116
[Nphe(1)]nociceptin-(1-13)NH2 selectively antagonizes nociceptin effects in the rabbit isolated ileum 115
Role of nociceptin/orphanin FQ receptors in the decrease of mucosal mast cells caused by acute stress in the rat colon. 115
Nociceptin/orphanin FQ receptor knockout rats: in vitro and in vivo studies. 115
Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay 114
Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist 114
Assessment of the activity of a novel nociceptin/orphanin FQ analogue at recombinant human nociceptin/orphanin FQ receptors expressed in Chinese hamster ovary cells 113
In vitro and in vivo pharmacological characterization of the novel neuropeptide S receptor ligands QA1 and PI1 113
Structure-activity relationship study on Tyr9 of urotensin-II(4-11): identification of a partial agonist of the UT receptor. 112
In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant 112
Sudden death from pulmonary thromboembolism: chronobiological aspects 111
Pharmacological profile of hemokinin 1: a novel member of the tachykinin family 111
[Arg(14), Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies 111
Nociceptin/orphanin FQ inhibits ischaemia-induced glutamate efflux from rat cerebrocortical slices 110
Studies on the antinociceptive effect of [Nphe(1)]nociceptin(1-13)NH2 in mice 110
B1 and B2 kinin receptors in various species 110
Inhibitory effect of NMDA receptor activation on quisqualate-stimulated phosphatidylinositol turnover in the human cerebral cortex 110
Desensitisation of native and recombinant human urotensin-II receptors. 110
null 110
Urotensin II stimulates plasma extravasation in mice via UT receptor activation 110
Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands 109
Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120 109
Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. 109
Effects of intrathecal nocistatin on the flexor reflex and its interaction with orphanin FQ nociceptin 109
Totale 12.986
Salva come PNG Salva come JPEG
Categoria #
all - tutte 154.321
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.834
Totale 157.155
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.796 0 0 0 0 558 872 748 783 660 653 331 191
2020/20214.830 378 445 264 570 307 489 167 567 154 634 577 278
2021/20223.644 144 369 312 217 203 190 217 236 156 302 313 985
2022/20233.455 379 160 114 414 572 485 177 315 470 21 196 152
2023/20241.781 196 229 88 50 99 310 74 142 35 30 53 475
2024/20252.091 183 203 631 254 820 0 0 0 0 0 0 0
Totale 32.810